Endometriosis: Pelvic Pain Phenotypes, Hormonal Suppression Ladder & Fertility Counselling

Endometriosis describes the presence of endometrium-like glands and stroma outside the uterine cavity. The ectopic tissue retains hormonal responsiveness, so cyclical proliferation, micro-bleeding, prostaglandin release and a sustained inflammatory cascade drive both nociceptive pain and progressive fibrosis—producing adhesions, distortion of pelvic anatomy and, over time, deep infiltrating nodules in the rectovaginal septum, bowel, bladder or ureter. Disease behaviour ranges from a few superficial peritoneal implants picked up incidentally at laparoscopy to a frozen pelvis with kissing endometriomas and bowel involvement; these phenotypes overlap rather than form a clean ladder.

The condition is best framed as a chronic, systemic, estrogen-driven inflammatory disease rather than a purely structural problem. Comorbid central sensitisation, pelvic floor hypertonicity, concurrent adenomyosis and uterine fibroids, plus the psychosocial burden of repeated pain episodes all shape the clinical picture. WHO emphasises that endometriosis can begin at menarche and persist into menopause, and that it affects trans men and non-binary individuals who menstruate—broaden history-taking accordingly rather than assuming a narrow demographic.

Two complementary frameworks dominate practice. The revised American Society for Reproductive Medicine (rASRM) score grades surgical findings into stages I–IV and was originally designed to predict fertility outcomes. The #ENZIAN classification—endorsed within the ESHRE 2022 guideline—captures peritoneal, ovarian and deep infiltrating disease and is increasingly used pre-operatively from imaging (transvaginal ultrasound and MRI). Neither system reliably predicts pain. Nurses do not stage disease, but recognising the language on imaging and operative reports prevents miscommunication during fasting, bowel preparation, stoma counselling and theatre-list prioritisation.

↔On a small screen, swipe or scroll sideways to see the full table.

Pain disability and quality-of-life scores remain the most important “stage” for the patient in front of you—mirror the descriptors used in your local imaging report rather than retrofitting older grading from memory.

Endometriosis rarely arrives with a single complaint—history-taking should systematically explore cyclical and non-cyclical patterns plus their impact on work, education, relationships and mood. ESHRE 2022 lists the core cluster: dysmenorrhoea, deep dyspareunia, dysuria, dyschezia, painful rectal bleeding or haematuria, shoulder-tip pain, catamenial pneumothorax, cyclical cough/haemoptysis/chest pain, cyclical scar swelling and pain, fatigue, and infertility.

Typical menstrual phenotype

• Progressive dysmenorrhoea that is poorly responsive to standard analgesia and increasingly precedes the bleed (pelvic pain phenotype).
• Heavy menstrual bleeding with clots, plus inter-menstrual spotting in a subset of patients.
• Deep pain during intercourse reproducible by uterosacral or posterior fornix tenderness on bimanual exam.
• Cyclical dysuria or pain with defecation that worsens during menses.

Non-cyclical and atypical patterns

• Chronic non-menstrual pelvic pain merging into lower back pain and pelvic floor tenderness—often reflecting central sensitisation rather than active lesion size.
• Bloating, fatigue, nausea and bowel-habit change—frequently mislabelled as IBS for years before specialist review.
• Subfertility with missed periods on ovulation suppression or, conversely, normal cycles with no obvious anovulatory pattern.
• Adolescents may present with severe dysmenorrhoea, school absence and recurrent admissions for analgesia—not “growing pains.”
• Asymptomatic endometriosis discovered incidentally at laparoscopy or imaging exists; treat the patient, not the picture, and avoid escalating therapy in the absence of pain or fertility concerns.

The pathophysiology is multifactorial and incompletely understood. Retrograde menstruation with ectopic implantation, coelomic metaplasia, lymphovascular dissemination, stem-cell theories and aberrant immune surveillance are all invoked—reality is likely a combination, with estrogen-driven inflammation and altered progesterone signalling sustaining lesions. Genetic susceptibility is real: a first-degree relative with endometriosis raises risk several-fold.

Heightened-suspicion profiles

• Early menarche, short cycles (<27 days), prolonged or heavy bleeds, low body mass index and nulliparity.
• Obstructive Müllerian anomalies (e.g. imperforate hymen, non-communicating uterine horn) in adolescents presenting with severe cyclical pain.
• Family history of endometriosis or chronic pelvic pain.
• Coexistent gynaecological pathology—leiomyomatous disease and ovarian cysts frequently coexist, and patients labelled solely with polycystic ovary syndrome can still harbour endometriosis driving their pain.

Modifiable risk reduction is modest but worth raising in clinic: smoking cessation, optimising body weight where indicated, and addressing iron status proactively when bleeding is heavy support overall reproductive health rather than “curing” the disease.

Clinical assessment

Take a systematic history covering cycle length, bleed pattern, pain timing relative to menses, dyspareunia, bowel/bladder symptoms, fertility plans, prior surgery, mental health and current opioid exposure. NICE NG73 (2024 update) and ESHRE 2022 advise that a normal pelvic examination does not exclude endometriosis—superficial peritoneal disease is frequently impalpable. Where examination is performed, document uterosacral nodularity, posterior fornix tenderness, fixed retroverted uterus, and any palpable adnexal mass. Pair the consultation with a structured pain assessment capturing functional impact, not just numerical scores.

Laboratory investigations

• Pregnancy test (β-hCG) in any reproductive-age patient with new pelvic pain—do not skip this “routine” step.
• Full blood count, ferritin and iron studies when bleeding is heavy or fatigue dominates—anaemia is common and may be treated alongside, not after, hormonal stabilisation.
• STI screen and urinalysis when pelvic inflammatory disease or urinary infection are plausible.
• Do not use CA-125 to make or refute the diagnosis—NICE NG73 explicitly advises against this. Reserve CA-125 interpretation for adnexal mass work-up under gynae-oncology pathways, not for symptom screening.

Imaging

Transvaginal ultrasound by an experienced operator is first-line, even when bimanual examination is normal. It identifies endometriomas, deep disease involving bowel, bladder or ureter (using sliding-sign and compartment assessment), and alternative pathology. Pelvic MRI is reserved for specialist services to map deep infiltrating disease before surgery; transabdominal ultrasound is acceptable when transvaginal scan is declined or not feasible. Crucially, normal imaging does not rule out endometriosis—superficial peritoneal disease is essentially invisible non-invasively.

Diagnostic laparoscopy

Both NICE NG73 and ESHRE 2022 have moved laparoscopy off its pedestal as the universal gold standard. Consider it when imaging is normal but symptoms persist despite empirical therapy, when surgical treatment is the chosen pathway, or when staging is needed to plan fertility care. When performed, a tissue biopsy at the time of laparoscopy is reasonable but not mandatory for visually classical disease.

Diagnostic anchors for handover

• Symptom cluster (cyclical/non-cyclical), duration of symptom history, prior diagnostic delay.
• Imaging report verbatim where deep disease is described—do not paraphrase “bowel involvement” into vague language.
• Current and prior hormonal therapy with response and side effects—prevents repeating ineffective regimens.

↔On a small screen, swipe or scroll sideways to see the full table.

Treatment is structured around three competing priorities—pain control, fertility, and long-term disease/quality-of-life impact—balanced against side effects, comorbidities and patient preference. NICE NG73 and ESHRE 2022 both endorse early empirical therapy alongside investigation rather than gating treatment on imaging or surgery.

First-line management

• Analgesia ladder. A short trial (typically up to 3 months) of paracetamol or an NSAID—ibuprofen as a familiar example—alone or in combination, with timing aligned to the menstrual cycle. Counsel on gastric and renal precautions.
• Hormonal first-line. Combined hormonal contraception (pill, patch or ring) or a progestogen (oral norethisterone acetate, dienogest, depot medroxyprogesterone acetate, or the levonorgestrel intrauterine system) suppresses cyclical activity. Medroxyprogesterone and norethindrone are commonly used progestogens; choice is shaped by VTE risk, migraine with aura, breast-feeding status and bleeding pattern preference.
• Adjunctive control of heavy bleeding. Tranexamic acid during menses for symptomatic relief in suitable patients (verify VTE history first).
• Iron repletion. Oral ferrous sulfate when ferritin is depleted; coach on alternate-day dosing and gastrointestinal tolerance, escalate to IV iron when oral therapy fails or is poorly tolerated.

Second-line / specialist pharmacology

• GnRH agonists (e.g. leuprolide, goserelin) and GnRH antagonists (e.g. elagolix, relugolix–estradiol–norethisterone combinations where licensed) for refractory pain. Always paired with add-back low-dose hormone therapy to mitigate hypoestrogenic bone loss and vasomotor symptoms; coordinate with endocrine/specialist gynaecology.
• Aromatase inhibitors in selected refractory or postmenopausal cases under specialist supervision.
• Multidisciplinary chronic pain support—pelvic floor physiotherapy, cognitive behavioural therapy, and neuropathic adjuncts (e.g. tricyclics, gabapentinoids) when central sensitisation features dominate, prescribed cautiously and reviewed regularly.

Surgical management

Laparoscopic excision or ablation of peritoneal lesions, cystectomy or drainage and ablation of endometriomas, and deep disease excision involving bowel/bladder/ureter at specialist centres with colorectal and urology partnership. Hysterectomy ± bilateral salpingo-oophorectomy is reserved for completed family with refractory symptoms and is not a guaranteed cure, particularly in the presence of deep disease. NICE NG73 advises that diagnostic laparoscopy be combined with treatment of visible disease where appropriate, with prior consent.

Special populations

• Adolescents: NICE recommends referral of those aged 17 and under with suspected or confirmed endometriosis to paediatric/adolescent gynaecology or a specialist centre; document school impact and mental health proactively.
• Patients prioritising fertility: Avoid prolonged ovulation suppression as the “default”; combine surgery for endometriomas/deep disease with assisted reproduction (IUI or IVF) per fertility specialist plan.
• Pregnancy: Most analgesia and all hormonal endometriosis therapies are paused; manage pain with paracetamol-led regimens and obstetric input. Screen for placenta accreta spectrum and preterm-labour risk in deep disease cohorts.
• Postmenopausal patients: Symptoms usually wane, but recurrence on systemic estrogen-only HRT after hysterectomy/oophorectomy is documented—favour combined or progestogen-balanced HRT under specialist guidance.

This section bundles operational expectations spanning emergency, ward and ambulatory interfaces.

1. Empirical therapy is not a luxury. Initiate analgesia and hormonal treatment alongside referral and imaging—not after them. Document a clear review point (typically 3–6 months) and the criteria that will trigger escalation.
2. Pain trajectory monitoring. Use a structured pain diary capturing cyclical timing, opioid exposure, sleep, sexual function and work/school absence; this dataset drives meaningful escalation conversations far better than a single 0–10 score.
3. Treatment-failure triggers. Persistent disabling pain after 3–6 months of an appropriately dosed regimen, escalating opioid use, new bowel/bladder cyclical symptoms, or suspected endometrioma growth should pull the patient up the ladder rather than into yet another repeat prescription.
4. Drug interactions and safety. Combined contraception is contraindicated in migraine with aura, hypertension, smokers ≥35 and active VTE; reconcile with medication reconciliation at every transition. GnRH analogues require add-back planning for bone health.
5. Perioperative preparation. Confirm bowel preparation only when explicitly ordered (deep disease excision), arrange cross-match where relevant, and ensure consent covers stoma, ureteric stent and adnexal procedures rather than narrow “laparoscopy” language.
6. Mental-health integration. Screen for depression and anxiety at every review—WHO and ESHRE both highlight the psychosocial burden as part of the disease, not a separate problem.
7. Specialist referral thresholds. NICE NG73 mandates referral to a specialist endometriosis centre for endometrioma, deep disease involving bowel/bladder/ureter, and extra-pelvic disease.

• Subfertility—often the presenting complaint when pain has been normalised for years.
• Endometrioma rupture, ovarian torsion and adhesion-related pain syndromes.
• Bowel obstruction from deep infiltrating disease; hydronephrosis from ureteric involvement.
• Iron deficiency anaemia from chronic heavy menstrual bleeding, with downstream cognitive and cardiovascular impact.
• Chronic pelvic pain syndromes with central sensitisation and pelvic floor dysfunction—often persisting after technically successful surgery.
• Mental-health comorbidity—depression, anxiety, post-traumatic features after repeated dismissive consultations.
• Modestly increased risk of certain ovarian cancers (clear-cell, endometrioid)—not a screening trigger in isolation, but a reason to take new postmenopausal symptoms seriously.
• Pregnancy complications—miscarriage, preterm birth and placenta praevia signals are reported; communicate with antenatal teams when conception occurs.

True primary prevention of endometriosis is not currently possible. Clinically meaningful “prevention” targets are diagnostic delay, complication accumulation and disease progression: take cyclical pain seriously at first presentation (especially in adolescents), avoid years of escalating analgesia without a hormonal pathway discussion, and refer promptly when first-line therapy fails. Where surgery is performed, fertility-aware tissue-sparing techniques and meticulous adhesion prevention reduce future morbidity. Lifestyle counselling around smoking cessation, regular exercise and balanced nutrition is reasonable but should never be presented as a cure.

Endometriosis behaves as a chronic relapsing disease for most patients. Many achieve good symptom control with structured medical therapy, but recurrence after surgery is common—reported in roughly 20–50% over five years depending on disease stage, surgical completeness and post-operative hormonal suppression. Symptoms typically attenuate around menopause yet do not disappear universally, and unopposed estrogen HRT can reactivate disease in oophorectomised patients. Counselling should anchor expectations: endometriosis is managed, not cured; the realistic goal is liveable function, fertility where desired, and avoidance of escalation traps such as opioid dependency or repeat ineffective surgery. Communicate this honestly without nihilism—most patients can build a durable plan when education is consistent across teams.

Bedside monitoring & deterioration cues

• Track pain score, opioid exposure, ability to mobilise, oral intake and urine output each shift in admitted patients—do not rely on the chronic-pain label to mask new pathology.
• Repeat abdominal assessment after analgesia wears off—rebound or guarding that emerges later may signal endometrioma rupture or coexistent surgical pathology.
• Quantify menstrual loss objectively (pads/tampons per hour, clot size, presyncope) when bleeding accompanies pain.
• Monitor intake and output closely after deep-disease surgery; new oliguria after ureteric work warrants immediate escalation.
• Vital sign trend assessment with attention to tachycardia disproportionate to pain—anaemia plus blood loss can mask early hypovolaemia in fit reproductive-age patients.

Communication and documentation

Document cyclical pattern, current hormonal regimen with last dose, fertility goals (and clarity on whether ovulation suppression should be paused), prior imaging or surgical findings, opioid history, mental-health support, and named escalation triggers. Many patients have already faced years of dismissive encounters—use validating language, avoid defaulting to “anxiety” attributions, and translate radiology reports into plain English in the chart so other nurses can act confidently.

Cross-team coordination

Endometriosis care frequently crosses gynaecology, colorectal, urology, fertility, pain management, mental health and primary care. Track which team holds the active escalation lead at any time; flag this in handover. When patients are seen for unrelated issues (e.g. surgery, antenatal booking), reconcile their hormonal regimen explicitly rather than assuming a default contraceptive entry on the chart is current.

Activate emergency or rapid-access gynaecology pathways when:

• Severe sudden pelvic pain with peritonism, syncope, hypotension or tachycardia.
• Pain plus a positive pregnancy test—evaluate for ectopic pregnancy regardless of the prior endometriosis label.
• New unilateral flank pain, anuria or visible haematuria—suspect ureteric obstruction or stone.
• Catamenial haemoptysis, pneumothorax features, or shoulder-tip pain during menses.
• Signs of bowel obstruction—vomiting, distension, absolute constipation—particularly in known deep disease.
• Rapidly enlarging adnexal mass, postmenopausal new-onset pelvic pain or weight loss—evaluate with malignancy in mind.
• Symptoms of severe anaemia (presyncope, dyspnoea, chest pain) with heavy bleeding.

In each scenario, secure IV access, send baseline bloods including pregnancy testing, escalate concurrently to senior nursing and medical leadership, and prepare imaging/theatre logistics rather than waiting for outpatient review.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and a compact cloze on the topic of endometriosis recognition (cyclical / non-cyclical pelvic-pain phenotypes), the structured hormonal-suppression ladder (combined hormonal contraceptive, progestogen, GnRH analogue ± add-back) and fertility / surgical / adenomyosis pathways with explicit ovarian-torsion / endometrioma-rupture / bowel / urinary obstruction red flags.